Inspire Medical Systems (INSP) shares plummeted 6.06% in pre-market trading on Tuesday, February 11, 2025, after multiple analysts lowered their price targets on the medical device company.
The sell-off was primarily driven by analysts revising down their expectations for the stock's future performance. Truist Securities cut its price target on INSP to $235 from $250, although it maintained a Buy rating. Meanwhile, Wells Fargo also reduced its price target on INSP to $195 from $198.
No other significant news or events were reported that could have triggered the sharp decline in INSP's stock price. The downward revisions in analysts' price targets appear to be the primary reason behind the pre-market plunge, as investors reacted negatively to the lowered expectations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。